Campaigner Jayne on her legacy and life after cancer WalesOnline, United Kingdom - They are told that they are being offered Herceptin because of breast-cancer sufferer Jayne Sullivan?s one-woman crusade to make it available on the NHS. ...
Cancer battle turns into dance Bonner Springs Chieftain, USA - Nov 25, 2008 I have Her2, an aggressive form of breast cancer; the drug of choice, Herceptin, targets the Her2 and goes after it just as aggressively. ...
Drugs you can't have Stuff.co.nz, New Zealand - Nov 30, 2008 Around 400 women have Her2-positive early stage breast cancer and could benefit from a year- long course of Herceptin. Who is missing out? ...
Cancer Institute lands new director Pittsburgh Post Gazette, PA - Nov 13, 2008 By Mark Roth, Pittsburgh Post-Gazette One of the nation's top breast cancer researchers has been chosen to head the University of Pittsburgh Cancer...
Source: Google News
Recent News and Articles on the Keywords: cancer + herceptin + web Related to the article below (Last Update: 8/7/2008)
Monogram Announces 2008 Second Quarter Financial Results MarketWatch - Jul 29, 2008 These activated protein complexes are believed to mediate resistance to Herceptin(R) in patients with breast cancer and are targets of other cancer drugs in ...
Hooray for Blockbuster Drugs City Journal, NY - Aug 1, 2008 Improvements in treatment for some cancers have been nothing short of astonishing: partly because of therapies like Taxol, Herceptin, and Arimidex, ...
FDA: Genentech's Avastin Tied To Several Cases Of Anemia CNNMoney.com - Jul 14, 2008 On Thursday, the FDA issued an alert after Genentech said it received complaints of damaged or broken vials of its breast-cancer drug Herceptin. ...DNA
SUVs, CEOs and WCs Medical Marketing and Media, NY - Jul 31, 2008 Prescribing information: The initial clinical data on Herceptin made the product look like a failure. Only later, when a diagnostic test revealed that it ...
Genentech Announces Second Quarter 2008 Results WELT ONLINE, Germany - Jul 14, 2008 ... Genentech initiated a Phase III combination study (BETH) of Avastin and Herceptin? (Trastuzumab) for patients with adjuvant HER2-positive breast cancer. ...DNA
Biz break: SunPower to build nation's biggest solar power system San Jose Mercury News, USA - Jul 11, 2008 South San Francisco-based Genentech has warned doctors it has received complaints of broken or otherwise damaged vials of its cancer-fighting drug Herceptin...
Source: Google News
CANCER: Enhanced: Addiction to Oncogenes--the Achilles Heal of Cancer - IB Weinstein - Science, 2002 - sciencemag.org ... titled "Drug therapy for breast cancer genes: Herceptin antibody therapy." Cancer.gov offers an information page about Herceptin. The Imaginis Web site offers ...
CANCER THERAPY: Antibodies Stage a Comeback in Cancer Treatment - S Dickman - Science, 1998 - sciencemag.org ... a browser that does not support current Web standards. ... At Genentech, researchers
designed an anti-breast cancer antibody called Herceptin to attack a ...
Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer - E Radzikowska, E Szczepulska, M Chabowski, I … - European Respiratory Journal, 2003 - Eur Respiratory Soc ... Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer.
E. Radzikowska , E. Szczepulska , M. Chabowski and I. Bestry ...
[PDF]Strategies for supporting consumer health information seeking - AT McCray, NC Ide, RR Loane, T Tse - Medinfo, 2004 - lhncbc.nlm.nih.gov ...Web Application Search Results Analysis and Suggestions ... details page on
ClinicalTrials.gov for the sample query, ?stage ii breast cancerherceptin olympus ...
Source: Google Scholar
NICE recommends Herceptin for early breast cancer
NICE has recommended Herceptin ( Trastuzumab ) for women with early stage HER2-positive breast cancer, except where there are concerns about the woman’s cardiac function.
The recommendations are as follows:
1.1 Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence ( whichever is the shorter period ), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy ( neoadjuvant or adjuvant ) and radiotherapy ( if applicable ).
1.2 Cardiac function should be assessed prior to the commencement of therapy and Trastuzumab treatment should not be offered to women who have a left ventricular ejection fraction ( LVEF ) of 55% or less, or who have any of the following:
• a history of documented congestive heart failure
• high-risk uncontrolled arrhythmias
• angina pectoris requiring medication
• clinically significant valvular disease
• evidence of transmural infarction on electrocardiograph ( ECG )
• poorly controlled hypertension.
1.3 Cardiac functional assessments should be repeated every 3 months during Trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then Trastuzumab treatment should be suspended. A decision to resume Trastuzumab therapy should be based on a further cardiac assessment and a fully informed discussion of the risks and benefits between the individual patient and their clinician.
